Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: radretumab, l19il2, as-1409 +2 | 0.81 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 8 Parkinson's papers of 2,949 | 0.71 |
| pathways Reactome | 30 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 4697
Sealed predictions
- FN1 in dopamine neurons, braak+0.22 (p 0.570) → +0.26 (p 0.493)receipt 4704
Swarm cases
receipt 4704: FN1 in dopamine neurons, braak
- power
- full sample +0.16 (p 0.538, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.32 (p 0.201, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.214, n 18). could be the mix.
- skeptic
- leave-one-out range +0.04 to +0.23, sign flips 0; without severely affected donors +0.16 (p 0.538, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FN1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts